Albumin therapy for acute ischemic stroke: a meta-analysis

Area of Science:

• Neurology
• Clinical Trials
• Medical Research

Background:

• Human serum albumin (HSA) demonstrates efficacy in rodent ischemic stroke models.
• Clinical trial results for albumin therapy in human ischemic stroke patients are controversial.
• Quantitative analysis is needed to assess neurofunctional outcomes in ischemic stroke patients treated with albumin.

Purpose of the Study:

• To quantitatively analyze the neurofunctional outcomes of patients with ischemic stroke treated with albumin.
• To evaluate the efficacy of albumin therapy in the acute stage of ischemic stroke.
• To determine the long-term neurological benefits of albumin administration in ischemic stroke patients.

Main Methods:

• A meta-analysis of published studies was conducted.
• Searches were performed in PubMed, Embase, and Cochrane Library in July 2020.
• Four studies involving 1611 patients were included in the analysis.

Main Results:

• No statistically significant difference in good neurological outcomes was observed between the albumin group (39.8%) and the control group (39.1%).
• The odds ratio for good neurological outcomes was 1.04 (95% CI 0.85-1.27).
• Albumin therapy in the acute stage of ischemic stroke did not show a beneficial effect on long-term neurological function.

Conclusions:

• Albumin therapy administered during the acute phase of ischemic stroke offers no significant benefit for long-term neurological function in patients.
• Increased risk of complications, such as pulmonary edema, necessitates caution when considering albumin therapy for acute ischemic stroke.
• Further research may be needed to identify specific patient subgroups who might benefit from albumin therapy, if any.